![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 291, Issue 1, 367-373, October 1999
Gene
Expression at the Transcriptional Level in Bleomycin Hamster Model of
Lung Fibrosis1
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California
| |
Abstract |
|---|
|
|
|---|
This study was undertaken to investigate whether treatment with the
antifibrotic drug pirfenidone (PD) down-regulates the bleomycin
(BL)-induced overexpression of transforming growth factor (TGF)-
gene in the lungs. Hamsters were intratracheally
instilled with SA or BL (6.5 U/kg/4 ml) under anesthesia. They were fed a diet containing 0.5% PD or the same control diet (CD) without the
drug 2 days before and throughout the study. After the animals were
sacrificed, their lungs were appropriately processed. The BL treatment
elevated the total influx of inflammatory cells, including macrophages,
by severalfold at different days in bronchoalveolar lavage fluid (BALF)
from hamsters in BL + CD groups, relative to the corresponding SA + CD
control groups. Treatment with PD significantly (P
.05) suppressed the influx of inflammatory cells and macrophages at
day 7 in the BL + PD groups, relative to the corresponding BL + CD
groups. In addition, the levels of TGF-
in BALF from hamsters in BL + CD groups were elevated by 2.6- to 4.5-fold at different days,
relative to the corresponding SA + CD groups. Treatment with PD
significantly (P
.05) reduced the TGF-
protein in BALF from BL + PD groups at 14 and 21 days, when compared
with the corresponding BL + CD groups. The intratracheal instillation
of BL significantly (P
.05) elevated the TGF-
mRNA at 7, 14, and 21 days in BL + CD groups, relative to the corresponding SA + CD groups, and treatment with PD significantly (P
.05) suppressed the TGF-
gene expression
in BL + PD groups at these times, when compared with the corresponding
BL + CD groups. Nuclear runoff studies revealed that PD suppressed the
BL-induced increase in TGF-
gene transcription by 33%. It was
concluded that one of the mechanisms for antifibrotic effect of PD is
its ability to suppress the BL-induced overexpression of TGF-
gene at the transcriptional level.
| |
Introduction |
|---|
|
|
|---|
Interstitial
pulmonary fibrosis (IPF), which is characterized by an excess
deposition of extracellular matrix (ECM) in the interstitial spaces of
the lung, is the end stage of many lung disorders (Crouch,
1990
). The bleomycin (BL) model of lung fibrosis involves an
initial injury to the lung, followed by an influx of inflammatory cells
that release cytokines that increase the synthesis of collagen by the
mesenchymal cells, resulting in an increased connective tissue
deposition (Bitterman et al., 1983
). The inflammatory response includes
an initial phase involving an increase in the number of neutrophils
followed by a sustained increase in the number of macrophages and
lymphocytes at the later phases in the lungs (Chandler et al., 1983
).
The alveolar macrophages are known to be the predominant cell type in
the alveolar space and are known to play a crucial role in inflammation
and wound repair. In the BL-induced lung injury, there is an increase
in the influx of macrophages into the lung, and these activated
macrophages produce a variety of cytokines such as interleukin (IL)-1,
tumor necrosis factor-
, platelet-derived growth factor (PDGF), and transforming growth factor (TGF)-
(Martinent et al., 1987
; Jordana et al., 1988
; Piguet et al., 1989
; Khalil et al., 1989
) in the lung.
TGF-
is known to play a central role in modulating the inflammatory
response and in regulating the pathogenesis of pulmonary fibrosis
(Khalil et al., 1989
, 1991
).
TGF-
is known to exist in five different isoforms, and types I, II,
and III have been identified in mammals (Roberts and Sporn, 1990
). Type
I is the isoform known to be most implicated in fibrosis (Border and
Noble, 1994
). Numerous resident and recruited cell types, including
activated macrophages, platelets, lymphocytes, epithelial cells, and
fibroblasts, are known to release TGF-
by paracrine or autocrine
mechanisms at the site of lung inflammation and injury (Gauldie et al.,
1993
). Three different receptor isoforms of TGF-
have been
identified on a variety of cell types. TGF-
mediates most of its
actions via type I and type II receptors and it plays a regulatory role
in initiating, maintaining, and amplifying the effects of other
chemoattractants and cytokines involved in the pathogenesis of lung
injury. TGF-
is known to influence the metabolism and turnover of
ECM by increasing its deposition and inhibiting its degradation
(Roberts and Sporn, 1990
). In the process of wound healing, TGF-
elevation often leads to an exuberant deposition of ECM. An increased
level of TGF-
is known to precede increases in collagen,
fibronectin, and proteoglycan deposition (Westergren et al., 1993
).The
elevated levels of TGF-
in animal models of lung fibrosis, and in
the bronchoalveolar lavage fluid (BALF) and lung tissues of patients suffering from pulmonary fibrosis, are well documented by various investigators (Brokelman et al., 1991; Gurujeyalakshmi et al., 1998
).
Treatment for IPF continues to remain a challenge for all physicians
and researchers. The currently available therapeutic measures for
treatment of IPF are inadequate. In addition, these measures are
associated with severe side effects (Giri, 1990
). Because TGF-
is
central to the molecular mechanism for an excess deposition of ECM,
suppressing its overproduction constitutes a rational therapeutic
approach in the management of pulmonary fibrosis.
Our laboratory has previously demonstrated the antifibrotic and
therapeutic potential of pirfenidone (PD) in a BL hamster model of lung
fibrosis (Iyer et al., 1995
, 1998
). We have also demonstrated that PD
down-regulates the BL-induced overexpression of procollagen I and III
gene expression. (Iyer et al., 1999
) There is evidence that TGF-
stimulates procollagen gene expression (Raghow et al., 1985
, 1987
;
Khalil et al., 1989
; Breen et al., 1992
). We tested the hypothesis that
PD perhaps acts more proximally and initially down-regulates the
BL-induced overexpression of TGF-
gene, followed by a subsequent
down-regulation of BL-induced overexpression of lung procollagen genes,
as demonstrated in our earlier study (Iyer et al., 1999
). To test this
hypothesis, we have evaluated the effects of PD treatment on the influx
of inflammatory cells and TGF-
in the BALF and expression of TGF-
message in the lungs at various times during the course of BL-induced
lung fibrosis in hamsters.
| |
Materials and Methods |
|---|
|
|
|---|
Treatment of Animals. Male Golden Syrian hamsters weighing 90 to 110 g were purchased from Simonsens, Inc. (Gilroy, CA). Hamsters were housed in groups of four, in facilities with filtered air and constant temperature and humidity. All care was in accordance with the National Institutes of Health Guide for Animal Welfare Act. The hamsters were allowed to acclimate in facilities for 1 week before any treatments. A 12-h light/dark cycle was maintained. The hamsters had access to water and either pulverized Rodent Laboratory Chow 5001 (Purina Mills, St. Louis, MO) or the same pulverized chow containing 0.5% PD (w/w). The animals were fed these diets starting 2 days before intratracheal (IT) instillation and continuing throughout the course of the experiment. Under pentobarbital anesthesia, hamsters were IT instilled with saline (SA; 4 ml/kg) or BL (6.5 U/4 ml/kg). Animals were randomly divided into four experimental groups: SA-instilled with a control diet (CD; SA + CD); SA-instilled with the PD diet (SA + PD); BL-instilled with the control diet (BL + CD); and BL-instilled with the PD diet (BL + PD).
The animals were sacrificed at 3, 7, 14, and 21 days after BL or SA instillation and their lungs were removed, freeze clamped in liquid N2, and then stored at
80°C until use for
mRNA and transcription analysis. Simultaneously, five animals from each group were sacrificed by i.p. injection of sodium pentobarbital (90-120 mg/kg), followed by exsanguination. Their lungs were lavaged three times, using 4 ml of sterile SA in each wash in situ, according to the method of Giri and coworkers (1981)
80°C until use. One
milliliter of BALF was used to determine the total cell count and
differential analysis of macrophage numbers. The remaining BALF was
centrifuged at 4°C for 10 min at 1,500 rpm. The supernatant was
aspirated for TGF-
1 assay.
Total and Differential Cell Counts in BALF.
Total cell
number in BALF was estimated directly by Coulter Counter (Model F;
Coulter Electronics Inc., Hialeah, FL) and macrophage cell numbers were
obtained from differential cell counts. For differential cell counts,
the slides were prepared according to the method of Wilcox et al.
(1988)
and a total of 500 cells were counted.
TGF-
1 Level in BALF.
The BALF was obtained
from five hamsters in each group at various times after SA or BL
instillation. The TGF-
levels in the BALF were assayed using the
commercially available Predicta TGF-
enzyme-linked immunosorbent
assay kit (GENZYME Diagnostics, Cambridge, MA). The
enzyme-linked immunosorbent assay kit contained a 96-well microtiter
plate with immunomobilized mouse monoclonal antibody to TGF-
with a
reported sensitivity of 0.05 ng/ml. The activation of the samples to
release the active TGF-
, and the rest of the assay were carried out
as described per manufacturer recommendations. The standard curve was
generated using the TGF-
standard provided with the kit. The TGF-
assays were carried out in duplicate and the results were reported as
the mean of five samples in picogram per lung of total BALF recovered.
Total RNA Isolation and Hybridization Analysis.
The animals
were sacrificed by decapitation at various times and their lungs were
quickly dissected out after SA or BL instillation. They were freeze
clamped and dropped in liquid nitrogen and stored at
80°C. The
total RNA from the whole lung was isolated using RNeasy total RNA
extraction kit, according to the manufacture's instructions (Qiagen,
Chatsworth, CA). After isolation, the RNA was quantitated and checked
for integrity. Northern blot experiments were performed as described
previously (Gurujeyalakshmi et al., 1996
). Briefly, 5 µg of RNA was
electrophoresed through 1% agarose in 2.2 M formaldehyde gels and
transferred to a nylon membrane. The membrane was air dried for 20 min,
UV cross-linked, and prehybridized at 42°C for 2 h in a solution
containing 50% formamide, 5× sodium chloride sodium phosphate
ethylenediamine tetraacetic acid, 0.3% sodium dodecyl sulfate, and 200 µg/ml sheared salmon sperm DNA. Radiolabeled probe was prepared by
random primer method (Bio-Rad, Richmond, CA). The membranes were
hybridized either with TGF-
1 cDNA, or 18S rRNA cDNA
probe at 42°C for 16 h. RNA hybridization and washings were done
as described previously (Gurujeyalakshmi et al., 1996
). Relative
intensities of either TGF-
or 18S band were determined using a
dual-wavelength flying spot-scanning densitometer (model CS-9301PC;
Shimadzu, Columbia, MD). The results were expressed as the ratio of the
signal intensity for TGF-
1 mRNA/18S rRNA bands in the
same lane to limit variations in the quantity of RNA loaded in each lane.
Nuclear Runoff Studies.
The nuclei from the whole lung were
isolated from hamsters in all the groups, and the transcription assay
was carried out by the method of Gurujeyalakshmi and coworkers (1998)
.
Plasmids containing cDNA inserts of TGF-
1 and 18S rRNA
were isolated and linearized with the appropriate restriction enzymes.
Twenty micrograms of plasmid with cDNA inserts were slot blotted onto
nylon membrane strips, air dried, and UV cross-linked. Plasmid pBR322
with no cDNA insert was included as a control for nonspecific binding. The membrane strips were prehybridized and then hybridized with buffer
containing 32P-labeled transcripts (4-6 × 106 cpm/assay). The RNA-DNA binding was evaluated by
autoradiography and densitometry.
Molecular Probes.
TGF-
1 cDNA, containing a
1.05-kb EcoRI fragment was obtained from R. Derynk
(Genentech, South San Francisco, CA). The 18S ribosomal RNA clone
PN29III, with a 0.752-kb BamHI and SphI
cDNA insert were obtained from the American Type Culture Collection (Rockville, MD). The plasmid pBR322 containing no cDNA insert was
purchased from Pharmacia (Piscataway, NJ). The plasmids were isolated
and purified using the Qiagen gel extraction kit and treated to
complete restricted endonuclease digestion before use (Qiagen,
Chatsworth, CA).
Statistical Analysis.
Data were expressed as the mean ± S.E. Statistical differences among SA + CD, SA + PD, BL + CD, and BL + PD groups at the corresponding times were analyzed using two-way
ANOVA, and a value of P
.05 was
considered to be the minimum level of statistical significance. The
t test was applied where two groups were involved, and a
value of P
.05 was considered to be the minimum
level of statistical significance.
| |
Results |
|---|
|
|
|---|
Influx of Inflammatory Cells in BALF.
The effects of SA or BL
instillation, with or without PD in diet, on the influx of inflammatory
cells in BALF are summarized in Fig. 1.
The total number of cells recovered in BALF from hamsters in the SA + CD group was almost the same as in SA + PD groups. IT instillation of
BL significantly increased the total cell counts in BALF from BL + CD
groups by 223, 310, 473, and 293% at 3, 7, 14, and 21days, when
compared with the corresponding SA + CD control groups, respectively.
Treatment with PD significantly inhibited the influx of total cells in
BALF from hamsters in the BL + PD group at day 7, when compared with
the BL + CD group at the same day.
|
Effects of PF on Macrophages in BALF.
Figure
2 demonstrates the effect of PD on the
number of macrophages in BALF at various times after SA or BL
instillation. There were no statistically significant differences in
the number of macrophages in BALF from SA + CD and SA + PD groups at 3, 7, 14, and 21 days. Treatment with BL significantly elevated the number
of macrophages in BL + CD groups by 3-, 4.3-, and 3.2-fold of the
corresponding SA + CD controls at 7, 14, and 21 days, respectively. However, treatment with PD statistically reduced the number of macrophages in the BL + PD group by 58% at day 7, when compared with
the BL + CD group at the same time point.
|
Effects of PF on TGF-
Levels in BALF.
The effects of PF on
the TGF-
protein levels in BALF at various time points after SA or
BL instillation are shown in Fig. 3. The
TGF-
levels in SA + CD and SA + PD groups were similar at all time
points. The IT instillation of BL caused significant increases in the
TGF-
levels in BALF from hamsters in BL + CD groups by 255, 284, 290, and 452%, when compared with the corresponding SA + CD controls
at 3, 7, 14, and 21 days, respectively. Treatment with PD suppressed
the BL-induced increases in the TGF-
levels significantly in BL + PD
groups by 78 and 47% at 14 and 21 days, respectively, when compared
with the corresponding BL + CD groups.
|
Effects of PF on TGF-
Gene Expression in Lung.
The effects
of dietary intake of PF on the lung TGF-
gene expression in hamsters
receiving SA or BL IT are shown in Fig. 4. The Northern blot technique was used
in the gene expression studies. The levels of lung TGF-
mRNA in
groups SA + CD and SA + PD were similar to each other at all time
points and remained unchanged throughout the study period. The IT
instillation of BL significantly up-regulated the TGF-
gene
expression at 7, 14, and 21 days by 270, 425, and 301% in the BL + CD
groups, respectively, when compared with the corresponding SA + CD
groups. Treatment with PF down-regulated the BL-induced overexpression
of TGF-
mRNA at all time points in the BL + PD groups, and
significant reductions occurred at 7, 14, and 21 days by 60, 75, and
62%, respectively, compared with the corresponding BL + CD groups. Figure 5 represents the Northern blot and
densitometric reading showing the overexpression of the TGF-
gene in
the BL+ CD group and its down-regulation by PD treatment in the BL+ PD
group.
|
|
Effects of PF on TGF-
gene Expression in Lung at the
Transcriptional Level.
We carried out the nuclear run-off
transcription assay to determine whether the down-regulation of TGF-
gene in the BL + PD groups occurred at the transcriptional level. The
assay was performed as described previously by Gurujeyalakshmi and
coworkers (1996)
. The nuclei from the lungs of hamsters in SA + CD, SA + PD, BL + CD, and BL + PD groups were isolated at 14 days. The nascent
transcripts were labeled using 32P-UTP and hybridized with
the probes as described in Materials and Methods. The
labeled transcripts that hybridized to the cDNA of TGF-
1
were significantly reduced by 33% in the BL + PD group when compared
with the BL + CD group, as shown in Table
1 and Fig.
6. The transcription of TGF-
in the SA + CD and SA + PD was extremely low (data not shown), when compared with
the BL + CD and BL + PD groups. We observed that the transcription of the gene encoding 18S rRNA in lung nuclei of BL + CD and BL + PD groups
was almost identical. Our results demonstrate that PF down-regulates
the expression of TGF-
gene at the transcriptional level. This would
partly explain the subsequently observed down-regulation in TGF-
gene expression and TGF-
protein production.
|
|
| |
Discussion |
|---|
|
|
|---|
In this study, a variety of experiments were performed to
determine the mechanisms by which PD treatment inhibits the BL-induced increased production of TGF-
. Our investigation focused on this potent cytokine, which is in part derived from alveolar macrophages. The macrophages are known to play a critical role in the pathogenesis of BL-induced pulmonary damage, including the orchestration of both
inflammatory and fibroproliferative events associated with the fibrotic
processes of the lung. The alveolar macrophages regulate the
inflammatory phase by releasing a variety of proinflammatory cytokines
such as IL-1, tumor necrosis factor-
, macrophage inflammatory protein-1
, and chemotactic cytokines such as IL-8. They also influence the fibrotic phase by releasing growth factors such as PDGF,
fibroblast growth factor, and insulin growth factor-1, which are
mitogenic to mesenchymal cells and release cytokines that are directly
fibrogenic like those of TGF-
(Shaw and Kelly, 1995
). Previous
studies have demonstrated the influx of macrophages and their
activation during the course of BL-induced lung fibrosis (Chandler et
al., 1983
; Khalil et al., 1989
). It is well documented that TGF-
is
involved in BL-induced lung fibrosis and its level in the BALF peaks to
about 30-fold of the controls in BL-treated animals (Khalil et al.,
1989
). TGF-
functions as an amplifier of inflammatory response by
acting as a potent chemoattractant to the monocytes and macrophages,
and it also autoinduces its own production (Wahl et al., 1987
). After
macrophages are activated to secrete TGF-
, the process results in
continued activation, recruitment, and secretion of TGF-
, which
remains elevated throughout the entire course of the fibroproliferative
process. It seems that there is a positive feedback loop that
facilitates an increased production of TGF-
by activated cells.
(Wahl, 1994
). Our findings that BL-treated hamsters in BL + CD groups
had significantly greater influx of total cells and macrophages, and
consequently greater amounts of TGF-
in the BALF at almost all time
points of the study than the hamsters in SA + CD groups, lend credence
to the proposed concept of a positive-feedback loop of a sustained
production of increased amount of TGF-
by the activated macrophages
in the BL + CD groups. Treatment with PF generally suppressed the
BL-induced increases in the TGF-
levels of the BALF from hamsters in
BL + PD groups, and significant decreases occurred in these groups, compared with BL+CD groups at 14 and 21 days. Treatment with PF had no
effect on the BL-induced increases in the influx of total cells and
macrophages in BL + PD groups, except on day 7. On this day, the influx
of both total cells and macrophages was reduced by more than 50% in
the BL + PD group, compared with the BL + CD group. The significance of
this marked reduction in the influx of inflammatory cells on this day
is not clear. It is possible that a marked reduction in the number of
macrophages may contribute to decreased levels of TGF-
at later time
points. It is puzzling that the decreased influx of macrophages on day
7 did not correlate with the decreased levels of TGF-
in the BALF
from hamsters in the BL + PD group on this day. This would imply that
there are other possibilities, besides macrophages, that may account
for decreased levels of TGF-
in the BALF from hamsters treated with PD in the BL + PD groups. These include: 1) PF may directly act not
only on the macrophages, but also on the epithelial cells and
fibroblasts and compromise their ability to synthesize and release
TGF-
; and 2) PF may be directly inhibiting the activity of serine
proteases required to convert the latent form of TGF-
into the
active form in a manner similar to that of plasmin (Khalil et al.,
1996
). Regardless of the mechanisms, our data suggest that one of the
mechanisms for anti-inflammatory and antifibrotic effects of PF is its
ability to suppress the BL-induced increased production of biologically
active form of TGF-
.
In addition to inhibition of TGF-
, PF treatment may elicit its
anti-inflammatory and antifibrotic effects in BL + PD groups by other
mechanisms. It has been previously shown that PD down-regulates the
expression of the intercellular adhesion molecule (Kaneko et al.,
1998
), which is an adhesion molecule and necessary for infiltration of
some inflammatory cells in lung (Von Andrian et al., 1991
). It has also
been shown that PD scavenges reactive oxygen species (ROS) in
vivo (Iyer et al., 1995
) and in vitro (Valleyathan et al., 1996
)
conditions. It is possible that PD could be exerting its
anti-inflammatory and antifibrotic effects in other ways, including
decreasing the expression of adhesion molecules, and being able to
directly scavenge the ROS generated by the influx of inflammatory cells
and/or by the redox cycling of BL/DNA/Fe2+
complex (Sugiura and Kikuchi, 1978
). Thus, a diminution in the severity of ROS-induced lung damage by PF treatment in BL + PD groups
may subsequently attenuate the ensuing cascade of events involved in
the development of lung fibrosis.
TGF-
is a chemoattractant for fibroblasts (Postlethwaite et al.,
1987
), and it induces proliferation of fibroblasts through the
production of growth factors such as PDGF. PDGF is known to stimulate,
activate, and differentiate the fibroblasts to a more aggressive
phenotype fibroblast population that relentlessly synthesizes connective tissue proteins (Roberts and Sporn, 1990
). Because TGF-
is known to influence mesenchymal cell proliferation via stimulating
PDGF
-receptors (Yamakage et al., 1992
), the suppression of TGF-
by PD could effect the mitogenic activity of TGF-
on mesenchymal
cells directly or indirectly. Our laboratory has recently demonstrated
that treatment with PD inhibited the BL-induced increases in the
PDGF-AA and -BB levels in BALF from hamsters in BL + PD groups
(Gurujeyalakshmi et al., 1999
). The observed reduction in the lung
collagen content in this group of hamsters could be due to reduced
mesenchymal cell proliferation secondary to inhibitory effects of PD on
TGF-
and PDGF production.
TGF-
is known to have a direct profibrotic action by virtue of its
stimulatory effects on the synthesis of ECM proteins. For instance, it
has been shown that TGF-
increases expression of fibronectin and
collagen genes at the transcriptional and post-transcriptional levels
(Raghow et al., 1985
, 1987
) It also stabilizes the ECM by preventing
its proteolytic degradation by decreasing the synthesis of
matrix-degrading proteinases such as serine protease,
metalloproteinase, and collagenase (Roberts and Sporn, 1990
). TGF-
also increases the synthesis of specific proteinase inhibitors such as
tissue inhibitors of metalloproteinase and plasminogen activator
inhibitor (Edwards et al., 1987
). These effects of TGF-
eventually
lead to an aberrant and excess deposition of ECM (Sporn et al., 1987
). Our results indicate that BL treatment significantly up-regulated the
TGF-
gene expression at all time points of the study. This could be
caused by an increased transcription of TGF-
gene, as demonstrated
in this study. However, we cannot rule out the increased TGF-
mRNA
stability as another contributing factor to increased levels of TGF-
message in the lung of hamsters in BL + CD groups. Our results also
demonstrate that treatment with PD significantly down-regulated the
BL-induced overexpression of TGF-
in BL + PD groups at 7, 14, and 21 days. The reduction in the TGF-
mRNA levels by PD treatment in BL + PD groups is being mediated at the transcriptional level because the
nuclear runoff studies revealed that PF caused a significant reduction
in the synthesis of TGF-
transcripts in hamsters in this group
compared with hamsters in the BL + CD group. These results explain our
previous findings that reduced TGF-
levels are associated with the
down-regulation of the transcription of the procollagen genes and
collagen content (Iyer et al., 1999
). The data obtained in the present
study indicate that treatment with PF suppressed the BL-induced
overexpression of TGF-
production and TGF-
mRNA at the
transcriptional level and subsequently suppressed the BL-induced
overexpression of procollagen genes in the lungs. These effects finally
lead to a reduction in the synthesis and deposition of collagen in the
lung of hamsters in BL + PD group.
Other studies involving neutralizing TGF-
by its antibody (Giri et
al., 1993
) and binding TGF-
by decorin (Giri et al., 1997
)
demonstrated amelioration of BL-induced lung fibrosis. However, the
stage at which TGF-
can be suppressed is critical because corticosteroids are somewhat beneficial at the earlier stages of
fibrosis, when TGF-
is derived from macrophages. In the advanced stages of IPF, when TGF-
production is associated with epithelial cells, corticosteroids fail to elicit any beneficial response (Carrington et al., 1978
; Pierce et al., 1989
; Khalil et al., 1993
).
Our results suggest that the beneficial effects of PF against BL-induced lung fibrosis involve the suppression of TGF-
effects at
the proinflammatory and profibrogenic phases of the fibrotic processes.
Thus, treatment with PD starting at the inflammatory stages of fibrosis
may prove to be more beneficial to patients with early diagnosis of
IPF.
| |
Footnotes |
|---|
Accepted for publication June 21, 1999.
Received for publication February 19, 1999.
1 This work was supported by National Heart, Lung and Blood Institute Grant R01 HL-56262
Send reprint requests to: Dr. Shri N. Giri, Dept. of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA 95616. E-mail: sngiri{at}ucdavis.edu
| |
Abbreviations |
|---|
IPF, interstitial pulmonary fibrosis; ECM, extracellular matrix; SA, saline; IT, intratracheal; BL, bleomycin; PD, pirfenidone; TGF, transforming growth factor; IL, interleukin; PDGF, platelet-derived growth factor; BALF, bronchoalveolar lavage fluid; CD, control diet; ROS, reactive oxygen species.
| |
References |
|---|
|
|
|---|
in the tissue fibrosis.
New Engl J Med
331:
1286-1292
and fibroblast collagen synthesis in chronic pulmonary inflammation.
Am J Respir Cell Mol Biol
6:
146-152.
is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.
Proc Natl Acad Sci USA
88:
6642-6646
modulates the expression of collagenase and metalloproteinase inhibitor.
EMBO J
6:
1899-1904[Medline].
on bleomycin induced accumulation of lung collagen in mice.
Thorax
48:
959-966
mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis.
Am J Respir Cell Mol Biol
18:
334-342
and fibroblast synthesis in chronic pulmonary inflammation.
J Exp Med
170:
727-737
secreted by alveolar macrophages after in vivo bleomycin injury.
Am J Respir Cell Mol Biol
15:
252-259[Abstract].
in idiopathic pulmonary fibrosis.
Am J Resp Cell Mol Biol
5:
155-162.
secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat.
J Clin Invest
92:
1812-1818.
.
J Exp Med
165:
251-256
increases steady state levels of type I procollagen and fibronectin mRNAs post transcriptionally in cultured human dermal fibroblasts.
J Clin Invest
79:
1258-1288.
's, in
Peptide Growth Factors and Their Receptors: Handbook of Experimental Pharmacology (Sporn MB andRoberts AB eds) vol 95/I, pp 419-472,
Springer-Verlag, Heidelberg, Germany.
.
J Cell Biol
105:
1039-1045
2 integrins in vivo.
Proc Natl Acad Sci USA
88:
7538-7542
in developing bleomycin-induced fibrosis in rats.
J Clin Invest
92:
632-637.
: The good, the bad, and the ugly.
J Exp Med
180:
1587-1590
induces monocyte chemotaxis and growth factor production.
Proc Natl Acad Sci USA
84:
5782-5788.
receptors by TGF-
in scleroderma fibroblasts.
J Exp Med
175:
1227-1234This article has been cited by other articles:
![]() |
A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF] |
||||
![]() |
T J Williams and J W Wilson Challenges in pulmonary fibrosis: 7 {middle dot} Novel therapies and lung transplantation Thorax, March 1, 2008; 63(3): 277 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Cho, D. C. Smith, M. H. Branton, S. R. Penzak, and J. B. Kopp Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 906 - 913. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Lee, T. H. Everett IV, D. Rahmutula, J. M. Guerra, E. Wilson, C. Ding, and J. E. Olgin Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure Circulation, October 17, 2006; 114(16): 1703 - 1712. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hirano, A. Kanehiro, K. Ono, W. Ito, A. Yoshida, C. Okada, H. Nakashima, Y. Tanimoto, M. Kataoka, E. W. Gelfand, et al. Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated Challenge Am. J. Respir. Cell Mol. Biol., September 1, 2006; 35(3): 366 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Azuma, T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, K. Nakata, Y. Taguchi, S. Nagai, H. Itoh, M. Ohi, et al. Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1040 - 1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Evans, T. V. Colby, J. H. Ryu, and A. H. Limper Transforming Growth Factor-{beta}1 and Extracellular Matrix-Associated Fibronectin Expression in Pulmonary Lymphangioleiomyomatosis Chest, March 1, 2004; 125(3): 1063 - 1070. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Bartram and C. P. Speer The Role of Transforming Growth Factor {beta} in Lung Development and Disease Chest, February 1, 2004; 125(2): 754 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Card, W. J. Racz, J. F. Brien, S. B. Margolin, and T. E. Massey Differential Effects of Pirfenidone on Acute Pulmonary Injury and Ensuing Fibrosis in the Hamster Model of Amiodarone-Induced Pulmonary Toxicity Toxicol. Sci., September 1, 2003; 75(1): 169 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Bates and A. M. Mercurio Tumor Necrosis Factor-{alpha} Stimulates the Epithelial-to-Mesenchymal Transition of Human Colonic Organoids Mol. Biol. Cell, May 1, 2003; 14(5): 1790 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Card, W. J. Racz, J. F. Brien, and T. E. Massey Attenuation of Amiodarone-Induced Pulmonary Fibrosis by Vitamin E Is Associated with Suppression of Transforming Growth Factor-beta 1 Gene Expression but Not Prevention of Mitochondrial Dysfunction J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 277 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Selman From Anti-inflammatory Drugs Through Antifibrotic Agents to Lung Transplantation : A Long Road of Research, Clinical Attempts, and Failures in the Treatment of Idiopathic Pulmonary Fibrosis Chest, September 1, 2002; 122(3): 759 - 761. [Full Text] [PDF] |
||||
![]() |
M. L. Hale, S. B. Margolin, T. Krakauer, C. J. Roy, and B. G. Stiles Pirfenidone Blocks the In Vitro and In Vivo Effects of Staphylococcal Enterotoxin B Infect. Immun., June 1, 2002; 70(6): 2989 - 2994. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Selman, T. E. King Jr., and A. Pardo Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy Ann Intern Med, January 16, 2001; 134(2): 136 - 151. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||